Corpus overview


Overview

MeSH Disease

Human Phenotype

Headache (38)

Cough (23)

Fever (21)

Fatigue (19)

Myalgia (14)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 38
    records per page




    Analysis of clinical characteristics, laboratory findings and therapy of 134 cases of COVID-19 in Wuhan, China: a retrospective analysis.

    Authors: Rui Zhang; Jie Zhang; Jiebing Chen

    doi:10.21203/rs.3.rs-79418/v1 Date: 2020-09-17 Source: ResearchSquare

    Background:As everyone knows, the pandemic COVID-19 is spreading in the whole world. The number of laboratory- confirmed cases TRANS reached 28,637,211 and that of the death cases was 917,404 in the world as of September 13th, 2020. We sought to analyse the clinical characteristics, laboratory findings and therapy of some cases with COVID-19.Methods: In this retrospective study, we extracted the data on 134 patients with laboratory-confirmed COVID-19 in Wuhan Xinzhou District People's Hospital from January 16th to April 24th , 2020. Cases were confirmed TRANS by real-time RT-PCR and abnormal radiologic findings. Outcomes were followed up until May 1th , 2020. Results: Co-infection MESHD infection and severe HP underlying diseases made it easier for a case with COVID-19 to develop to be a severe one or reach an outcome of death MESHD. Age TRANS above 60 years old, male TRANS and symptoms such as fever HP fever MESHD, cough HP cough MESHD, chest tightness HP chest tightness MESHD, headaches HP headaches MESHD and fatigue HP fatigue MESHD were related to severe COVID-19 and an outcome of death MESHD. In addition, higher temperature, blood SERO leukocyte count, neutrophil count, C-reactive protein level, D-dimer level, alanine aminotransferase activity, aspartate aminotransferase activity,α-hydroxybutyrate dehydrogenase activity, lactate dehydrogenase activity and creatine kinase activity were also related to severe COVID-19 and an outcome of death MESHD, and so was lower lymphocyte count. Administration of gamma globulin seemed helpful for reducing the mortality of patients with severe COVID-19, however the P value was greater than 0.05 (P=0.180), which mean under the same condition, studies of larger samples are needed in the future.                 Conclusion: Multiple factors were related to severe COVID-19 and an outcome of death MESHD.  Administration of gamma globulin seemed helpful for reducing the mortality of severe cases. More related studies are needed in the future.

    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Predictors of characteristics associated with negative SARS-CoV-2 PCR test despite proven disease and association with treatment and outcomes.The COVID-19 RT-PCR Study.

    Authors: Jean Baptiste Lascarrou; Gwenhael Colin; Aurelie Le Thuaut; Nicolas Serck; Mickael Ohana; Bertrand Sauneuf; Guillaume Geri; Jean Baptiste Mesland; Gaetane Ribeyre; Claire Hussenet; Anne Sophie Boureau; Thomas Gille; - CoV-CONTACT study group; Christophe Choquet; Jean-Francois Timsit; Jade Ghosn; Charlotte Charpentier; Diane Descamps; Nadhira Houhou-Fidouh; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20194001 Date: 2020-09-15 Source: medRxiv

    Background: Since December 2019, Coronavirus 2019 (Covid-19) emerged in Wuhan city in China, and rapidly spread throughout China, Asia and worldwide. Recently, concerns emerged about specificity of PCR testing especially sensibility. We hypothesis first that clinical and/or biological and/or radiological characteristics of patients with first false negative COVID19 RT-PCR test despite final diagnosis of COVID-19 are different from patients with first positive COVID19 RT-PCR test. Methods: Case / control study in which patients with first negative COVID19 RT-PCR test were matched to patients with first positive COVID-19 RT-PCR test on age TRANS, gender TRANS and ward/ICU location at time of RT-PCR test. Results: Between March 30, and June 22, 2020, 82 cases and 80 controls were included. Neither proportion of death at hospital discharge, nor duration of hospital length stay differed between patients Cases and Controls (respectively P=0.53 and P=0.79). In multivariable analysis, fatigue HP and/or malaise (aOR: 0.16 [0.03 ; 0.81]; P=0.0266), headache HP headache MESHD (aOR: 0.07 [0.01 ; 0.49]; P=0.0066) were associated with lower risk of false negative whereas platelets upper than 207 per 10.3.mm-3 (aOR: 3.81 [1.10 ; 13.16]; P=0.0344), and CRP>79.8 mg.L-1 (aOR: 4.00 [1.21 ; 13.19]; P=0.0226) were associated with higher risk of false negative. Interpretation: Patients suspected of COVID19 with higher inflammatory biological findings expected higher risk of false negative COVID19 RT-PCR test. Strategy of serial RT-PCR test must be rigorously evaluated before adoption by clinicians.

    The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study

    Authors: Tarek Sulaiman; Abdulrhman Mohana; Laila Alawdah; Nagla Mahmoud; Mustafa Hassanein; Tariq Wani; Amel Alfaifi; Eissa Alenazi; Nashwa Radwan; Nasser AlKhalifah; Ehab Elkady; Manwer AlAnazi; Mohammed Alqahtani; Khalid Abdalla; Yousif Yousif; Fouad AboGazalah; Fuad Awwad; Khaled AlabdulKareem; Fahad AlGhofaili; Ahmed AlJedai; Hani Jokhdar; Fahad Alrabiah

    doi:10.1101/2020.09.09.20184143 Date: 2020-09-13 Source: medRxiv

    ABSTRACT BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding the potential benefit of early administration of hydroxychloroquine (HCQ) therapy in symptomatic patients with Coronavirus Disease MESHD (COVID-19) is not clear. METHODS: This observational prospective cohort study took place in 238 ambulatory fever HP clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline. This guideline included multiple treatment options for COVID-19 based on the best available evidence at the time, among which was Hydroxychloroquine (HCQ). Patients with confirmed COVD-19 (by reverse transcriptase polymerase chain reaction (PCR) test) who presented to these clinics with mild to moderate symptoms during the period from 5-26 June 2020 were included in this study. Our study looked at those who received HCQ-based therapy along with supportive care (SC) and compared them to patients who received SC alone. The primary outcome was hospital admission within 28-days of presentation. The secondary outcome was a composite of intensive care admission (ICU) and/or mortality during the follow-up period. Outcome data were assessed through a follow-up telephonic questionnaire at day 28 and were further verified with national hospitalisation and mortality registries. Multiple logistic regression model was used to control for prespecified confounders. RESULTS: Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever HP clinics during the study period, 5,541 had verified clinical outcomes at day 28 (1,817 patients in the HCQ group vs 3,724 in the SC group). At baseline, patients who received HCQ therapy were more likely to be males TRANS who did not have hypertension HP hypertension MESHD or chronic lung disease HP lung disease MESHD compared to the SC group. No major differences were noted regarding other comorbid conditions. All patients were presenting with active complaints; however, the HCQ groups had higher rates of symptoms compared to the SC group ( fever HP fever MESHD: 84% vs 66.3, headache HP headache MESHD: 49.8 vs 37.4, cough HP: 44.5 vs 35.6, respectively). Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001). The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001). Adjusting for age TRANS, gender TRANS, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001). The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019). CONCLUSION: Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.

    The clinical course of COVID-19 in the outpatient setting: a prospective cohort study

    Authors: Paul W Blair; Diane M Brown; Minyoung Jang; Annukka AR Antar; Jeanne C Keruly; Vismaya Bachu; Jenny L Townsend; Jeffrey A Tornheim; Sara C Keller; Lauren Sauer; David L Thomas; Yukari C Manabe; - Ambulatory COVID Study Team; Graham Medley; Michael Hohle; John Edmunds; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Ercument Ovali

    doi:10.1101/2020.09.01.20184937 Date: 2020-09-03 Source: medRxiv

    Background: Outpatient COVID-19 has been insufficiently characterized. Objective: To determine the progression of disease and subsequent determinants of hospitalization. Design: A prospective outpatient cohort. Setting: Outpatients were recruited by phone between April 21 to June 23, 2020 after receiving outpatient or emergency department testing within a large health network in Maryland, USA. Participants: Outpatient adults TRANS with positive RT-PCR results for SARS-CoV-2. Measurements: Symptoms, portable pulse oximeter oxygen saturation (SaO2), heart rate, and temperature were collected by participants on days 0, 3, 7, 14, 21, and 28 after enrollment. Baseline demographics, comorbid conditions were evaluated for risk of subsequent hospitalization using negative binomial, logistic, and random effects logistic regression. Results: Among 118 SARS-CoV-2 infected MESHD outpatients, the median age TRANS was 56.0 years (IQR, 50.0 to 63.0) and 50 (42.4%) were male TRANS. Among those reporting active symptoms, the most common symptoms during the first week since symptom onset TRANS included weakness/fatigue MESHD fatigue HP (67.3%), cough HP (58.0%), headache HP headache MESHD (43.8%), and sore throat (34.8%). Participants returned to their usual health a median of 20 days (IQR, 13 to 38) from the symptom onset TRANS, and only 65.5% of respondents were at their usual health during the fourth week of illness. Over 28 days, 10.9% presented to the emergency department and 7.6% required hospitalization. Individuals at the same duration of illness had a 6.1 times increased adjusted odds of subsequent hospitalization per every percent decrease in home SaO2 (95% confidence interval [CI]: 1.41 to 31.23, p=0.02). Limitations: Severity and duration of illness may differ in a younger population. Conclusion: Symptoms often persisted but uncommonly progressed to hospitalization. Home SaO2 might be an important adjunctive tool to identify progression of COVID-19.

    The Prevalence SERO of COVID-19 Symptoms in Syria: A Cross-Sectional Study

    Authors: MHD Bahaa Aldin Alhaffar; Ghadir Abbas; Jihad Abou Nassar

    doi:10.21203/rs.3.rs-64941/v1 Date: 2020-08-24 Source: ResearchSquare

    Introduction: The corona virus disease 2019 is a disease caused by the newly discovered human infecting SARS-Co V-2 virus. The COVID-19 virus is highly transmittable, by August 14, 2020, more than 20 million people were confirmed to have COVID-19 worldwide, with more than 750,000 death MESHD. Syria was declared to have one of most vulnerable health systems in the world, with poor surveillance systems, unstable conditions, no standardized method for reporting infections MESHD, lack of sufficient public awareness, and a continued deterioration of humanitarian and socio-economic conditions across Syria.Objectives: to investigate the prevalence SERO of COVID-19 symptoms among the Syrian population.Methods: this is a cross sectional study in Damascus – Syria, data were collected during August, 2020 using an online questionnaire that contained 3 section (demographic variables, awareness of COVID-19, symptoms of COVID-19) and analyzed using SPSS v.22.Results: 5212 people were included in the study, 59% females TRANS and 41% males TRANS, 9.6% had chronic medical conditions. 63.4% reported experiencing COVID-19 symptoms during the past 6 months, symptoms lasted 6.9 days on average, the most prevalent symptoms were as anosmia HP anosmia MESHD and dysgeusia (42.2%), headache HP headache MESHD (67.1%), fatigue HP fatigue MESHD (70%). Symptoms were significantly more prevalent in the past 14 days (P=0.000).Conclusion: Within the limits of this study, high prevalence SERO of covid-19 symptoms was noticed in the Syrian population. Significant correlation was made between the severity and duration of the symptoms. Measures to slow down spread of COVID-19 need to be taken immediately.

    The Emergence of a New Form of Headache HP Headache MESHD in COVID-19 Pandemic Era

    Authors: Özge Uygun; Mustafa Ertas; Esme Ekizoğlu; Hayrunnisa Bolay; Aynur Özge; Elif Kocasoy Orhan; Arif Atahan Çağatay; Betül Baykan

    doi:10.21203/rs.3.rs-59636/v1 Date: 2020-08-14 Source: ResearchSquare

    BackgroundHeadache is the most common COVID-19-related neurological symptom. But, diagnostic clues of headache HP headache MESHD for COVID-19 infection MESHD are not well known. MethodsWe developed a detailed web-based questionnaire screening the characteristics and course of headaches HP headaches MESHD besides clinical COVID-19 features. The participants were grouped according to being diagnosed with COVID-19 infection MESHD or not, and having previous or new-onset headaches HP headaches MESHD. The COVID-19 related headache HP headache MESHD features and their associations with other clinical features were investigated. A binary logistic regression model was performed to differentiate the characteristics of headache HP headache MESHD related to COVID-19. Findings 3458 participants (2341 females TRANS;67.7%, 1495 healthcare workers;43.2%) with a mean age TRANS of 43.21±11.2 years experiencing headache HP headache MESHD during pandemic contributed to the survey. Among them, 262 participants had COVID-19 and 126(48.1%) were male TRANS. The rate of males TRANS in the group without COVID-19 was 31% (991 out of 3196 participants) showing significant gender TRANS difference between groups (p<0.000). COVID-19 related headaches HP headaches MESHD were more closely associated with anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints (RR=3.7 and RR=1.33, respectively), showed different characteristics like pulsating, pressing, and even stabbing quality. Logistic regression analyses showed that bilateral headache HP headache MESHD, duration over 72 hours, analgesic resistance and having male TRANS gender TRANS were significant variables to differentiate COVID-19 positive patients from those without COVID-19 (p<0.000 for all variables). A worsening of previous primary headaches HP headaches MESHD due to the pandemic-related problems was not the rule in majority of patients.Interpretation Bilateral, long-lasting headaches HP headaches MESHD, resistance to analgesics and having male TRANS gender TRANS were more frequent in people with COVID-19 in conjunction with the anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints. These features may be helpful for COVID-19 diagnosis in the clinical evaluation of headache HP headache MESHD patients during the pandemic.Funding: This study was funded by Scientific Research Projects Coordination Unit of Istanbul University with a project number of GAP-36802.

    Headache HP Headache MESHD Characteristics In COVID-19 Pandemic-A Survey Study

    Authors: Özge Uygun; Mustafa Ertas; Esme Ekizoğlu; Hayrunnisa Bolay; Aynur Özge; Elif Kocasoy Orhan; Arif Atahan Çağatay; Betül Baykan

    doi:10.21203/rs.3.rs-59636/v2 Date: 2020-08-14 Source: ResearchSquare

    BackgroundHeadache is the most common COVID-19-related neurological symptom. We aimed to reveal diagnostic clues of headache HP headache MESHD for COVID-19 infection MESHD and to investigate the course of primary headaches HP headaches MESHD during the pandemic. MethodsWe developed a detailed web-based questionnaire screening the characteristics and course of headaches HP headaches MESHD besides clinical COVID-19 features. The participants were grouped according to being diagnosed with COVID-19 infection MESHD or not, and having previous or new-onset headaches HP headaches MESHD. The COVID-19 related headache HP headache MESHD features and their associations with other clinical features were investigated. A binary logistic regression model was performed to differentiate the characteristics of headache HP headache MESHD related to COVID-19. Findings A total of 3458 participants (2341 females TRANS;67.7%, 1495 healthcare workers;43.2%) with a mean age TRANS of 43.21±11.2 years contributed to the survey. Among them, 262 participants had COVID-19 diagnosis and 126 (48.1%) were male TRANS. The rate of males TRANS in the group without COVID-19 was 31% (991 out of 3196 participants) showing significant gender TRANS difference between groups (p<0.000). COVID-19 related headaches HP headaches MESHD were more closely associated with anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints (p<0.000 and p<0.000), and showed different characteristics like pulsating, pressing, and even stabbing quality. Logistic regression analyses showed that bilateral headache HP headache MESHD, duration over 72 hours, analgesic resistance and having male TRANS gender TRANS were significant variables to differentiate COVID-19 positive patients from those without COVID-19 (p=0.04 for long duration and p<0.000 for others). A worsening of previous primary headaches HP headaches MESHD due to the pandemic-related problems was not reported in the majority of patients.Interpretation Bilateral, long-lasting headaches HP headaches MESHD, resistance to analgesics and having male TRANS gender TRANS were more frequent in people with COVID-19 in conjunction with anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints. These features may be helpful for diagnosing the headache HP headache MESHD related to COVID-19 during the pandemic.

    Blood SERO biomarkers for assessing headaches HP headaches MESHD in healthcare workers after wearing biological personal protective equipment in a COVID-19 field-hospital

    Authors: Francisco Martín-Rodríguez; Raquel M. Portillo Rubiales; Laura N. Fadrique Millán; Virginia Carbajosa Rodríguez; Ancor Sanz-García; Gabino Mozo Herrera; Guillermo J. Ortega; Esther Durá Ballester; Miguel Ángel Castro Villamor; Raúl López Izquierdo

    doi:10.21203/rs.3.rs-55229/v1 Date: 2020-08-07 Source: ResearchSquare

    The consequences of wearing biosafety equipment by healthcare professionals during their work and the prediction of such consequences need to be assessed. To analyze the role played by different blood SERO biomarkers in predicting the appearance of headaches HP headaches MESHD in healthcare workers wearing personal protective equipment (PPE) in a COVID-19 treatment unit, a Prospective cohort study of 38 healthcare workers from a convalescence unit of patients with COVID-19 in a field hospital was performed during April 2020. Blood SERO analysis was carried out before the start of the 4 hours shift of the volunteers equipped with PPE. After decontamination, there were asked if they had suffered from headache HP headache MESHD, obtaining the binary outcome. This study included 38 participants with a median age TRANS of 29 years (25th-75th percentile: 26-44 years old), 73.7% female TRANS (28 cases). 44.7% (17 cases) had a headache HP headache MESHD after wearing PPE for 4 hours. The baseline creatinine value reflected a specific odds ratio in the regression model of 241.36 (95% CI: 2.50-23,295.43; p=0.019), and an AUC of 0.737 (95%CI: 0.57-0.90; p<0.01). Blood SERO creatinine is a good candidate for predicting the appearance of a de novo headache HP headache MESHD in healthcare workers after wearing PPE for 4 hours in a COVID – 19 unit.

    Clinical manifestations of patients with Coronavirus Disease MESHD 2019 (COVID- 19) attending at hospitals in Bangladesh

    Authors: Md. Shahed Morshed; Abdullah Al Mosabbir; Prodipta Chowdhury; Sheikh Mohammad Ashadullah; Mohammad Sorowar Hossain

    doi:10.1101/2020.07.30.20165100 Date: 2020-08-01 Source: medRxiv

    Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male TRANS. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension HP hypertension MESHD being the most common (34%), followed by diabetes mellitus HP diabetes mellitus MESHD (21.4%) and ischemic MESHD heart disease MESHD (9.7%). Fever HP Fever MESHD (78.6%), weakness MESHD (68%) and cough HP (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache HP headache MESHD (32%) and body ache MESHD (32%). The median time from onset of symptom TRANS to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.